Novavax (NVAX)
(Delayed Data from NSDQ)
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Zacks News
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Why Novavax (NVAX) Stock Fell 19% on Friday
by Madeleine Johnson
Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -26.33% and -19.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.
5 Best Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was subdued last week. A slew of earnings results for the second quarter and a new report on consumer spending for June came in stronger than expected. But increasing cases of the delta variant of COVID-19 also weighed on risk-on sentiments.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $212.31 in the latest trading session, marking a +1.61% move from the prior day.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $192.48, marking a +0.12% move from the previous day.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $192.24, marking a -1.1% move from the previous day.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.
Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day
Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More
by Mark Vickery
The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.
Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.